Jones Keith Anthony purchased $6K of HUMA

Humacyte Inc. (HUMA) announced that the FDA extended the shelf life of its Symvess product from 18 to 36 months. The decision was based on stability data showing Symvess meets quality standards. The company's CEO noted the extension supports hospital adoption and reduces product waste. HUMA's stock is currently trading at $0.58, down 1.13%.

Ultragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.

Humacyte (HUMA) reported one-year results from its Phase 3 trial in The Lancet Digital Health, showing its bioengineered vessel (ATEV) outperformed standard AV fistulas in hemodialysis patients, especially high-risk groups. The company aims to advance ATEV for broader use. HUMA stock closed at $0.58, up 3.76%, and was at $0.59 in pre-market trading.

Humacyte (HUMA) reported Q2 2026 product revenue of $0.4M, up from $0.1M, driven by Symvess launch. V012 Phase III trial met primary endpoint, showing 91 more catheter-free days for ATEV vs. AV fistula. Company targets Nov. 2026 sBLA filing for dialysis access, with potential 2027 launch. Cash position is $80.3M post-June equity offering. Net loss was $36.8M, with $54.4M loss for H1 2026. Management noted slower-than-expected trauma market adoption and reimbursement pressures.

Humacyte Inc. (HUMA) published one-year Phase 3 trial results in The Lancet, showing its ATEV outperformed traditional methods for hemodialysis access in end-stage kidney disease patients. The study highlighted benefits for high-risk groups. The company plans to submit a supplemental BLA in 2H 2026 to expand Symvess's label.

Humacyte announced the publication of its V007 Phase 3 trial results in Lancet Digital Health. The trial focused on hemodialysis access. The company claims positive outcomes, which may impact its valuation.